New approaches in the treatment of hepatitis C

World Journal of Gastroenterology

Volumn 22, Issue 4, 2016, Pages 1421-1432

  González Grande, Rocío ^a   Jiménez Pérez, Miguel ^a   Arjona, Carolina González ^a   Torres, José Mostazo ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Direct acting antiviral agents; Hepatitis C; Outcome; Patients; Treatment

Indexed keywords

ASUNAPREVIR PLUS BECLABUVIR PLUS DACLATASVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ELBASVIR PLUS GRAZOPREVIR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; DEATH; DISEASE COURSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERANCE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEMODIALYSIS; HEPATITIS C; HUMAN; LIVER TRANSPLANTATION; PANGENOME; PATIENT SAFETY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE PERIOD; RECURRENT DISEASE; SUSTAINED VIROLOGIC RESPONSE; VIRAL CLEARANCE; ANTIVIRAL RESISTANCE; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; PATHOGENICITY; PHENOTYPE; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; PHENOTYPE; TREATMENT OUTCOME;

EID: 84977615349     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/WJG.V22.I4.1421     Document Type: Article

References (58)

1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61: S45-S57 [PMID: 25086286 DOI: 10.1016/j.jhep.2014.07.027]
2. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]
3. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]
4. Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132-142.e4 [PMID: 24704719 DOI: 10.1053/j.gastro.2014.03.051]
5. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 368: 1907-1917 [PMID: 23675659 DOI: 10.1056/NEJMra1213651]
6. Belperio PS, Backus LI, Ross D, Neuhauser MM, Mole LA. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system. J Manag Care Spec Pharm 2014; 20: 533-540 [PMID: 24856591]
7. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44 [PMID: 23281974 DOI: 10.1056/NEJMoa1208953]
8. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-426 [PMID: 24907224 DOI: 10.1016/S0140-6736(14)60538-9]
9. Amano M, Ishikawa H. [Pharmacological properties and clinical efficacy of daclatasvir (Daklinza®) and asunaprevir (Sunvepra®)]. Nihon Yakurigaku Zasshi 2015; 145: 152-162 [PMID: 25765498 DOI: 10.1254/fpj.145.152]
10. Keating GM. Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. Drugs 2015; 75: 675-685 [PMID: 25837989 DOI: 10.1007/s40265-015-0381-2]
11. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Müllhaupt B, Horsmans Y, Weiland O, Reesink HW, Rodrigues L, Hu YB, Podsadecki T, Bernstein B. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147: 359-365.e1 [PMID: 24818763 DOI: 10.1053/j.gastro2014.04.045]
12. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med 2015; 163: 1-13 [PMID: 25909356 DOI: 10.7326/M15-0785]
13. Hassanein T, Sims KD, Bennett M, Gitlin N, Lawitz E, Nguyen T, Webster L, Younossi Z, Schwartz H, Thuluvath PJ, Zhou H, Rege B, McPhee F, Zhou N, Wind-Rotolo M, Chung E, Griffies A, Grasela DM, Gardiner DF. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. J Hepatol 2015; 62: 1204-1206 [PMID: 25559328 DOI: 10.116/j.jhep2014.12.025]
14. European association for the study of the liver. EASL recommendation on treatment of hepatitis C 2015. Clinical practice guidelines: Management of hepatitis C virus infection. J Hepatol 2015; In press [DOI: 10.1016/j.jhep.2015.03.025]
15. AASLD and Infectious Diseases society of América (IDSA). Uptodate to recommendations for testing, managing and treating hepatitis C: management of acute HCV infection. Avaiable from: URL: http//www.hcvguidelines.org on 02/12/2014
16. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for noncirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401-408 [PMID: 23499158 DOI: 10.1016/S1473-3099(13)70033-1]
17. Mariño Z, van Bömmel F, Forns X, Berg T. New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut 2014; 63: 207-215 [PMID: 24253934 DOI: 10.1136/gutjnl-2013-305771]
18. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-1765 [PMID: 25078309 DOI: 10.1016/S0140-6736(14)61036-9]
19. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-413 [PMID: 24907225 DOI: 10.1016/S0140-6736(14)60494-3]
20. Jensen DM, Oleary J, Pcokros P, Sherman K, Kwo P, Mailliard M, Kowdley K, Muir A, Dickson R, Ramani A, Manns M, Lok A, Akushevich L, Nelson D, Fried M. Safety and efficacy of Sofosbuvir-containing regimens for hepatitis C: Real-world experience in a diverse, longitudinal observational cohort. [Abstract 45] 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Nov 7-11, 2014; Boston, MA, United States
21. Dieterich D, Bacon B, Flamm S, Kowdley K, Milligan S, Tsai N,Younossi Z, Lawitz E. Evaluation of sofosbuvir and simprevir based regimens in the TRIO network-Academic and community treatment of a real-world, heterogeneous population. [Abstract 46] 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Nov 7-11, 2014; 220A; Boston, MA, United States
22. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221 [PMID: 24428467 DOI: 10.1056/NEJMoa1306218]
23. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898 [PMID: 24725239 DOI: 10.1056/NEJMoa1402454]
24. Bhardwaj A, Kaur J, Wuest F, Knaus EE. Do nitric oxide-releasing drugs offer a potentially new paradigm for the management of cardiovascular risks in diabetes? Expert Rev Cardiovasc Ther 2014; 12: 533-536 [PMID: 24725228 DOI: 10.1056/NEJMoa1316366]
25. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P, Foster GR, Sulkowski MS, Xie W, Pilot-Matias T, Liossis G, Larsen L, Khatri A, Podsadecki T, Bernstein B. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370: 222-232 [PMID: 24428468 DOI: 10.1056/NEJMoa1306227]
26. Flamm SL, Everson GT, Charlton. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with descomensated cirrosis: preliminary results of a prospective, multicenter study. [Abstract L5] 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Nov 1-5, 2014; Boston, MA, United States
27. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-1603 [PMID: 24720703 DOI: 10.1056/NEJMoa1315722]
28. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-1982 [PMID: 24725237 DOI: 10.1056/NEJMoa1402869]
29. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983-1992 [PMID: 24795200 DOI: 10.1056/NEJMoa1402338]
30. Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourliere M, DeJesus E, Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385: 1087-1097 [PMID: 25467560 DOI: 10.1016/S0140-6736(14)61793-1]
31. Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385: 1075-1086 [PMID: 25467591 DOI: 10.1016/S0140-6736(14)61795-5]
32. Lawitz E, Poordad F, Gutierrez JA, Evans B, Hwang P, Howe A, Feng HP, Robertson M, Wahl J, Barr E, Hber B. C-SWITZ: Grazoprevir (MK-5172) Elbasvir (MK-8742) Sofosbuvir in treatment-naive patients with hepatitis C virus genotype 1 infection, with or without cirrhosis, for duration 4, 6, or 8 weeks (interim results). [Abstract LB-33] 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Nov 7-11, 2014; Boston, MA, United States
33. Poordad F, Sievert W, Mollison L, Brau N, Levin J, Sepe T, Lee S, Boyer N, Bronowicki JP, Jacobson IM, Boparai N, Hughes E, Swenson ES, Yin PD, on behalf of the UNITY-1 study team. Alloral, fixed-dosed combination therapy with daclatasvir/asunaprevir/beclabuvie for non-cirrhotic patients with chronic HCV genotype 1 infection: UNITY-1 phase 3 SVR 12 results. [Abstract LB-7] 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Nov 7-11, 2014; Boston, MA, United States
34. Muir AJ, Poordad F, Lalezari J, Everson GJ, Dore GJ, Kwo P, Hezode C, Pockros PJ, Tran A, Ramji A, Yang R, Hughes EA, Swenson ES, Yin PD on behalf of the UNITY-2 Study Team. All-Oral Fixed-Dose Combination Therapy With Daclatasvir/Asunaprevir/Beclabuvir, ± Ribavirin, for Patients With Chronic HCV Genotype 1 Infection and Compensated Cirrhosis: UNITY-2 Phase 3 SVR12 Results. JAMA 2015; 313:1736-1744 [DOI: 10.1001/jama.2015.3868]
35. Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir in combination with PegIFN and ribavirin dor 12 weeks provides high SVR rates in HCV-Infected getype 2 or 3 treatment-experienced patients with or without compensated cirrhosis: results from the LONESTAR-2 study. [Abstract 48] Asian Pacific Association for the Study of the Liver (APASL). Mar 12-15, 2014; Brisbane, Australia
36. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214853]
37. Bourlière M, Benali S, Ansaldi C, Le Folgoc G, Riso A, Lecomte L. Optimal therapy of genotype-2 chronic hepatitis C: what’s new? Liver Int 2015; 35 Suppl 1: 21-26 [PMID: 25529084 DOI: 10.1111/liv.12711]
38. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877 [PMID: 23607593 DOI: 10.1056/NEJMoa1214854]
39. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001 [PMID: 24795201 DOI: 10.1056/NEJMoa1316145]
40. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61: 1127-1135 [PMID: 25614962 DOI: 10.1002/hep.27726]
41. Gane E, Hyland RH, An Di, Pang PS, Symonds WT, McHutchinson, Stedman CA. Ledipasvis/sofosbuvir fixed-dose combination is safe and effective in difficult-to-treat populations including GT 3 patients, descompesated GT1 patients, and GT 1 patients with prior sofosbuvir experience. [Abstract 0-6] 49th European Association for the Study of the Liver International Liver Congress (EASL). Apr 9-13, 2014; London, United Kingdom
42. Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol 2013; 3: 514-520 [PMID: 23896281 DOI: 10.1016/j.coviro.2013.06.014]
43. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100-2107 [PMID: 23499440 DOI: 10.1016/S0140-6736(13)60247-0]
44. Kapoor R, Kohli A, Sidhartahan S, Sims Z, Pertersen T, Osinusi A, Nelson A, Silk R, Kotb C, Sugarman K, Lam BP, Pang PS, Subramanian M, McHutchison JG, Masur H, Kottilil S, Rustgi VK. Treatment of hepatitis C genotype 4 with ledipasvir and sofosbuvir for 12 weeks: results of the SYNERGY trial. [Abstract 240] 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Nov 7-11, 2014; Boston, MA, United States
45. Ruane PJ, Ain D, Stryker R, Meshrekey R, Soliman M, Wolfe PR, Riad J, Mikhail S, Kersey K, Jiang D, Massetto B, Doehle B, Kirby BJ, Knox SJ, McHutchison JG, Symonds WT. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2015; 62: 1040-1046 [PMID: 25450208 DOI: 10.1016/j.jhep.2014.10.044]
46. Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, García-Valdecasas JC, Navasa M, Rimola A, Rodés J. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396 [PMID: 12927925 DOI: 10.1016/S0168-8278(03)00310-6]
47. Curry MP, Forns X, Chung RT, Terrault NA, Brown R, Fenkel JM, Gordon F, O’Leary J, Kuo A, Schiano T, Everson G, Schiff E, Befeler A, Gane E, Saab S, McHutchison JG, Subramanian GM, Symonds WT, Denning J, McNair L, Arterburn S, Svarovskaia E, Moonka D, Afdhal N. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 100-107.e1 [PMID: 25261839 DOI: 10.1053/j.gastro.2014.09.023]
48. Jiménez-Pérez M, González-Grande R, Rando-Muñoz FJ. Management of recurrent hepatitis C virus after liver transplantation. World J Gastroenterol 2014; 20: 16409-16417 [PMID: 25469009 DOI: 10.3748/wjg.v20.i44.16409]
49. Burgess S, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T. Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients. Ann Pharmacother 2015; 49: 674-687 [PMID: 25770114 DOI: 1060028015576180]
50. Charlton M, Gane E, Manns MP, Brown RS, Curry MP, Kwo PY, Fontana RJ, Gilroy R, Teperman L, Muir AJ, McHutchison JG, Symonds WT, Brainard D, Kirby B, Dvory-Sobol H, Denning J, Arterburn S, Samuel D, Forns X, Terrault NA. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108-117 [PMID: 25304641 DOI: 10.1053/j.gastro.2014.10.001]
51. Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, Ryland K, Chervenak AE, Watt KD, Vargas HE, Keaveny AP. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015; 61: 1880-1886 [PMID: 25722203 DOI: 10.1002/hep.27770]
52. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, Gordon F, Levitsky J, Terrault NA, Burton JR, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375-2382 [PMID: 25386767 DOI: 10.1056/NEJMoa1408921]
53. Bunchorntavakul C, Maneerattanaporn M, Chavalitdhamrong D. Management of patients with hepatitis C infection and renal disease. World J Hepatol 2015; 7: 213-225 [PMID: 25729476 DOI: 10.4254/wjh.v7.i2.213]
54. Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat 2007; 14: 697-703 [PMID: 17875004]
55. Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, Cazorla C, Vittecoq D, Musset L, Decaux O, Ziza JM, Lambotte O, Cacoub P. PegIFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis 2014; 73: 831-837 [PMID: 23606708 DOI: 10.1136/annrheumdis-2012-202770]
56. Johnson RJ, Gretch DR, Couser WG, Alpers CE, Wilson J, Chung M, Hart J, Willson R. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994; 46: 1700-1704 [PMID: 7535369]
57. González-Grande R, Jiménez-Pérez M, Sáez-Gómez AB, Rodrigo-López JM. Metabolic syndrome after liver transplantation. In: Abdeldayem H, Allam N. Liver transplantation Technical issuesand complications. Croatia: ed InTech, 2012: 349-360
58. Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014; 59: 1293-1302 [PMID: 24122848 DOI: 10.1002/hep.26892]